<DOC>
	<DOCNO>NCT02910843</DOCNO>
	<brief_summary>Despite treatment locally advanced rectal cancer relapse frequent . Several attempt improve result therapy intensification show modest effect disease free survival ( DFS ) overall survival ( OS ) . Recent study addition sorafenib cediranib reveal promising effect tumor response acceptable toxicity . Regorafenib multi tyrosine kinase inhibitor ( TKI ) broad mechanism action . Therefore trial investigates similar result achieve sorafenib cediranib .</brief_summary>
	<brief_title>Neoadjuvant Treatment With Regorafenib Capecitabine Combined With Radiotherapy Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>Despite treatment locally advanced rectal cancer relapse frequent . Several attempt improve result therapy intensification show modest effect disease free survival ( DFS ) overall survival ( OS ) . Recent study addition sorafenib cediranib reveal promising effect tumor response acceptable toxicity . Regorafenib multi tyrosine kinase inhibitor ( TKI ) broad mechanism action . Therefore trial investigates similar result achieve sorafenib cediranib . The objective dose escalation part determinate safety , tolerability recommend dose . The objective expansion cohort ass efficacy characterize safety tolerability therapy .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent accord Swiss law ICH/GCP regulation trial specific procedure . Histologically confirm clinically advanced adenocarcinoma . pStage 2 3 accord AJCC 2012 , mrT3/4 N0 , mrTx N12 cM0 ( assessed mandatory CT scan thorax/abdomen , MRI pelvis ) . TNM classification ; recommend MRI quality assurance . Tumor locate low middle rectum ( caudal end define maximum 12 cm anal verge measure endoscopy ) . A multidisciplinary tumor board recommend neoadjuvant radiochemotherapy surgery . No DPD deficiency ( Dihydropyrimidinedehydrogenase DPD deficiency test mandatory ) . Carrier status predefined risk allele dihydropyrimidinedehydrogenase gene ( DPYD ) , define presence least one follow mutation : c.1679T &gt; G , c.1905+1G &gt; A , c.2846A &gt; T , c.11295923C &gt; G . Age 18 75 year . WHO performance status 01 . Adequate bone marrow function : neutrophil ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 100 g/L . Adequate hepatic pancreatic function : bilirubin ≤ 1.5 x ULN , AST/ALT/AP ≤ 2.5 x ULN , Lipase ≤ 1.5 x ULN . Adequate renal function ( calculated creatinine clearance &gt; 50 mL/min , accord formula CockcroftGault ) . INR ≤ 1.5 PTT ≤ 1.5 x ULN ( patient therapeutically anticoagulated allowed participate trial ) . If anti coagulation indicate trial treatment , low molecular weight heparin must use . Women childbearing potential use effective contraception , pregnant agree become pregnant trial treatment 8 week thereafter . A negative pregnancy test inclusion trial require woman childbearing potential . Men agree use effective contraception trial treatment 8 week thereafter . History hematologic primary solid tumor malignancy , unless remission least 3 year registration exception adequately treat cervical carcinoma situ localize nonmelanoma skin cancer . Concurrent recent ( within 30 day registration ) treatment experimental drug . Any prior treatment rectal cancer . Major surgery significant traumatic injury within 28 day registration ( colostomy accept ) . Concomitant strong CYP3A4 inhibitor ( e.g . clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telithromycin , voriconazole ) strong CYP3A4 inducer ( e.g . carbamazepine , phenobarbital , phenytoin , rifampin , St. John 's Wort ) within 28 day 5 drug halflives ( drug halflife patient know ) , whichever short , start trial treatment ( see http : //medicine.iupui.edu/ ) . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA IIIV ; see Appendix 5 ) , unstable angina pectoris , history myocardial infarction within last six month , serious arrhythmia require medication ( exception atrial fibrillation paroxysmal supraventricular tachycardia ) , significant QTprolongation ( QTc interval &gt; 460 msec ) , uncontrolled hypertension ( sustain systolic blood pressure &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg despite antihypertensive therapy ) . Patients evidence history bleed diathesis , irrespective severity . Any hemorrhage bleeding event ≥ CTCAE Grade 3 within 4 week prior start trial medication . Significant proteinuria : Positive dipstick 2+ great proteinuria ≥ 3.5g/24 h measure urine proteincreatinine ratio confirm ( ≥ Grade 3 , NCICTCAE v 4.0 ) . Patients know hepatopathy cirrhosis disease like Morbus Gilbert Meulengracht . Interstitial lung disease ongoing sign symptoms time informed consent . Known history human immunodeficiency virus ( HIV ) active chronic Hepatitis C Hepatitis B Virus infection uncontrolled active systemic infection require intravenous ( iv ) antimicrobial treatment . Lack physical integrity upper gastrointestinal tract malabsorption syndrome . History organ allograft . Known hypersensitivity trial drug , trial drug class , excipients formulation . Breastfeeding patient . Any concomitant drug contraindicate use trial drug accord Swissmedic approve product information . Any serious underlying medical , psychiatric , psychological , familial geographical condition , judgment investigator may interfere plan staging , treatment followup , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>Neoadjuvant treatment</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>locally advanced rectal cancer</keyword>
	<keyword>Phase Ib trial</keyword>
</DOC>